Subcortical vascular dementia biomarker pattern in mild cognitive impairment

Dementia and Geriatric Cognitive Disorders

Volumn 28, Issue 4, 2009, Pages 348-356

  Bjerke, Maria ^a   Andreasson, Ulf ^a   Rolstad, Sindre ^a   Nordlund, Arto ^a   Lind, Karin ^a   Zetterberg, Henrik ^a   Edman, Åke ^a   Blennow, Kaj ^a   Wallin, Anders ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Mild cognitive impairment; Subcortical vascular dementia

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; COGNITION DISORDERS; DEMENTIA, VASCULAR; ELECTROENCEPHALOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; TAU PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 70350393282     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000252773     Document Type: Article

References (42)

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308. (Pubitemid 29120227)
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M: Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117.
3. Aggarwal NT, Decarli C: Vascular dementia: emerging trends. Semin Neurol 2007; 27: 66-77.
4. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC: Subcortical ischaemic vascular dementia. Lancet Neurol 2002; 1: 426-436.
5. Jellinger KA: Diagnostic accuracy of Alzheimer's disease: a clinicopathological study. Acta Neuropathol 1996; 91: 219-220.
6. Gomez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT: Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurol Sci 1996; 16: 4491-4500.
7. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
8. Tomlinson BE, Blessed G, Roth M: Observations on the brains of demented old people. J Neurol Sci 1970; 11: 205-242.
9. Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J, Weber T, Kretzschmar HA, Poser S: Elevated levels of tauprotein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997; 225: 210-212. (Pubitemid 27191632)
10. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K: Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA 2001; 98: 6923-6928.
11. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ: Beta-amyloid-( 1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 10836-10840.
12. Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A: Neurofilament protein levels in CSF are increased in dementia. Neurology 1999; 52: 1090-1093.
13. Wallin A, Sjogren M: Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. Mech Ageing Dev 2001; 122: 1937-1949.
14. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A: The Goteborg MCI Study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 2005; 76: 1485-1490.
15. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240-246.
16. Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-194.
17. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Revised, ed 3. Washington, American Psychiatric Association, 1987.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
19. World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, World Health Organization, 1992.
20. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW: Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000; 59: 23-30. (Pubitemid 30479402)
21. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K: Simultaneous measurement of beta-amyloid(1- 42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005; 51: 336-345.
22. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C: Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996; 67: 2013-2018.
23. Ogata J: Vascular dementia: the role of changes in the vessels. Alzheimer Dis Assoc Disord 1999; 13(suppl 3):S55-S58.
24. Olsson Y, Brun A, Englund E: Fundamental pathological lesions in vascular dementia. Acta Neurol Scand Suppl 1996; 168: 31-38.
25. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM: Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). Neurology 1996; 46: 154-159.
26. Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A: Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 2001; 66: 510-516.
27. Friede RL, Samorajski T: Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat Rec 1970; 167: 379-387.
28. Lim ET, Sellebjerg F, Jensen CV, Altmann DR, Grant D, Keir G, Thompson EJ, Giovannoni G: Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler 2005; 11: 532-536.
29. Petzold A, Keir G, Warren J, Fox N, Rossor MN: A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis 2007; 4: 185-194.
30. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995; 26: 231-245.
31. Skoog I, Vanmechelen E, Andreasson LA, Palmertz B, Davidsson P, Hesse C, Blennow K: A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85- year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein e4 allele. Neurodegeneration 1995; 4: 433-442.
32. Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, Raiha I, Sourander L, Winblad B, Blennow K: Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow-up study. J Neurol Neurosurg Psychiatry 1998; 64: 298-305.
33. Rockwood K, Macknight C, Wentzel C, Black S, Bouchard R, Gauthier S, Feldman H, Hogan D, Kertesz A, Montgomery P: The diagnosis of 'mixed' dementia in the Consortium for the Investigation of Vascular Impairment of Cognition (CIVIC). Ann N Y Acad Sci 2000; 903: 522-528.
34. Trojanowski JQ, Schuck T, Schmidt ML, Lee VM: Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem 1989; 37: 209-215.
35. Sjogren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Granerus AK, Vanderstichele H, Vanmechelen E, Blennow K: Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70: 624-630.
36. Shi J, Yang SH, Stubley L, Day AL, Simpkins JW: Hypoperfusion induces overexpression of beta-amyloid precursor protein mRNA in a focal ischemic rodent model. Brain Res 2000; 853: 1-4.
37. Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao FF, Xu H, Zhang YW: Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem 2007; 282: 10873-10880.
38. Nagga K, Gottfries J, Blennow K, Marcusson J: Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 2002; 14: 183-190.
39. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-1992.
40. Herukka SK, Hallikainen M, Soininen H, Pirttila T: CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005; 64: 1294-1297.
41. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234.
42. Eriksson L JE, Kettaneh-Wold N, Trygg J, Wikström C, Wold S: Multi- and Megavariate Data Analysis Part II: Advanced Applications and Method Extensions, Revised and Enlarged Edition, ed 2. Umeå, Umetrics AB, 2006